Bharat Biotech may begin paediatric trials of Covaxin from June 1
It may get the license by the third quarter of this year
The trial will be on children aged between two and 18 years
The efficacy of the jab can be improved up to 100% protection via COVID-19 appropriate behaviour
The vaccine maker has developed Covaxin along with the nodal health agency, ICMR
Presently, pregnant and lactating mothers, special population, and children are not allowed to receive vaccines
